Curis CRIS
NASDAQ CRIS
$1.20 -0.07 (-5.51%)
At close: Sep 9, 2026 · 4:00 PM EDT

Curis (CRIS) Non Operating Interest Expenses (2013 - 2025)

Curis' (CRIS) quarterly Non Operating Interest Expenses came in at $314000.0 in Q4 2025, down 63.1% on a YoY basis from $851000.0 in Q4 2024, and down 64.52% quarter-over-quarter from $885000.0 in Q3 2025.

Analysis

Curis (CRIS) Non Operating Interest Expenses (2013 - 2025) Analysis & Trends

Curis (CRIS) has reported Non Operating Interest Expenses for 13 consecutive years, with $314000.0 the latest figure, recorded in Q4 2025.

  • For the quarter ending Q4 2025, Non Operating Interest Expenses fell 63.1% year-over-year to $314000.0; the trailing twelve-month figure through Jun 2026 stood at $1.2 million (down 28.93% YoY), and the FY2025 full-year result was $2.2 million, up 255.28% from the prior year.
  • Non Operating Interest Expenses declined to $314000.0 in Q4 2025 per CRIS's latest filing, from $885000.0 in the prior quarter.
  • Across five years, Non Operating Interest Expenses topped out at $1.7 million in Q4 2022 and bottomed at -$150000.0 in Q3 2024.
  • Historically, Non Operating Interest Expenses has averaged $703100.0 across 5 years, with a median of $744500.0 in 2023.
  • The sharpest annual moves came in 2024 and 2025: Non Operating Interest Expenses tumbled 124.23% in 2024, then jumped 5525.0% in 2025.
  • Over 5 years, Non Operating Interest Expenses stood at $1.1 million in 2021, then soared by 49.28% to $1.7 million in 2022, then slumped by 89.22% to $178000.0 in 2023, then surged by 378.09% to $851000.0 in 2024, then plunged by 63.1% to $314000.0 in 2025.
  • According to Business Quant data, Non Operating Interest Expenses over the past three periods registered $314000.0, $885000.0, and $434000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Operating Interest Expenses (Qtr)
1 Amgen 211.73 Bn 197.74 Bn 7.24 Bn 673.00 Mn
2 Gilead Sciences 180.92 Bn 177.74 Bn 6.22 Bn 247.00 Mn
3 Vertex Pharmaceuticals 132.16 Bn 124.30 Bn 2.84 Bn -
4 Regeneron Pharmaceuticals 82.89 Bn 74.90 Bn 3.93 Bn 11.00 Mn
5 Argenx Se 61.41 Bn 56.23 Bn 1.37 Bn -1.00 Mn
6 Moderna 53.99 Bn 48.85 Bn 52.00 Mn -
7 Alnylam Pharmaceuticals 34.48 Bn 31.18 Bn 992.69 Mn 82.05 Mn
8 Biogen 31.15 Bn 29.86 Bn 1.96 Bn -
9 Roivant Sciences 30.05 Bn 30.05 Bn 1.16 Mn -
10 Curis 2.57 Mn -3.05 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 314,000.00
Sep 30, 2025 885,000.00
Jun 30, 2025 434,000.00
Mar 31, 2025 552,000.00
Dec 31, 2024 851,000.00
Sep 30, 2024 -150,000.00
Jun 30, 2024 -8,000.00
Mar 31, 2024 -78,000.00
Dec 31, 2023 178,000.00
Sep 30, 2023 619,000.00
Jun 30, 2023 638,000.00
Mar 31, 2023 584,000.00
Dec 31, 2022 1.65 Mn
Sep 30, 2022 1.02 Mn
Jun 30, 2022 1.04 Mn
Mar 31, 2022 1.06 Mn
Dec 31, 2021 1.11 Mn
Sep 30, 2021 1.06 Mn
Jun 30, 2021 1.14 Mn
Mar 31, 2021 1.17 Mn